

Florian Selt

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2259111/publications.pdf>

Version: 2024-02-01

21
papers

2,329
citations

1163065

8
h-index

1474186

9
g-index

21
all docs

21
docs citations

21
times ranked

4375
citing authors

#	ARTICLE	IF	CITATIONS
1	DNA methylation-based classification of central nervous system tumours. <i>Nature</i> , 2018, 555, 469-474.	27.8	1,872
2	Next-generation sequencing in routine brain tumor diagnostics enables an integrated diagnosis and identifies actionable targets. <i>Acta Neuropathologica</i> , 2016, 131, 903-910.	7.7	203
3	Response to trametinib treatment in progressive pediatric low-grade glioma patients. <i>Journal of Neuro-Oncology</i> , 2020, 149, 499-510.	2.9	68
4	The Senescence-associated Secretory Phenotype Mediates Oncogene-induced Senescence in Pediatric Pilocytic Astrocytoma. <i>Clinical Cancer Research</i> , 2019, 25, 1851-1866.	7.0	55
5	Establishment and application of a novel patient-derived KIAA1549:BRAF-driven pediatric pilocytic astrocytoma model for preclinical drug testing. <i>Oncotarget</i> , 2017, 8, 11460-11479.	1.8	43
6	Preclinical drug screen reveals topotecan, actinomycin D, and volasertib as potential new therapeutic candidates for ETMR brain tumor patients. <i>Neuro-Oncology</i> , 2017, 19, 1607-1617.	1.2	39
7	Response in a child with a BRAF V600E mutated desmoplastic infantile astrocytoma upon retreatment with vemurafenib. <i>Pediatric Blood and Cancer</i> , 2018, 65, e26893.	1.5	21
8	Pediatric Targeted Therapy: Clinical Feasibility of Personalized Diagnostics in Children with Relapsed and Progressive Tumors. <i>Brain Pathology</i> , 2016, 26, 506-516.	4.1	14
9	A Cell-Based MAPK Reporter Assay Reveals Synergistic MAPK Pathway Activity Suppression by MAPK Inhibitor Combination in BRAF-Driven Pediatric Low-Grade Glioma Cells. <i>Molecular Cancer Therapeutics</i> , 2020, 19, 1736-1750.	4.1	13
10	MEDB-14. Clinical outcome of pediatric medulloblastoma patients with Li-Fraumeni syndrome. <i>Neuro-Oncology</i> , 2022, 24, i107-i107.	1.2	1
11	LGG-11. ESTABLISHMENT OF A HUMAN 3-DIMENSIONAL LOW-GRADE GLIOMA TUMOR MODEL IN INDUCED PLURIPOTENT STEM CELL DERIVED BRAIN ORGANIDS. <i>Neuro-Oncology</i> , 2019, 21, ii101-ii101.	1.2	0
12	LGG-04. MULTIOMIC ANALYSIS OF MAPK PATHWAY ACTIVITY IN PEDIATRIC PILOCYTIC ASTROCYTOMA. <i>Neuro-Oncology</i> , 2021, 23, i31-i32.	1.2	0
13	LGG-11. BH3-MIMETICS TARGETING BCL-XL SELECTIVELY IMPACT THE SENESCENT COMPARTMENT OF PILOCYTIC ASTROCYTOMA. <i>Neuro-Oncology</i> , 2021, 23, i33-i34.	1.2	0
14	Establishment of a 3-dimensional Low-grade Glioma Model in Induced Pluripotent Stem-cell-derived Brain Organoids. , 2019, 50, .		0
15	MODL-04. Drug screening in Disorders with Abnormal DNA Damage Response/Repair (DADDR) and <i>in vivo</i> validation. <i>Neuro-Oncology</i> , 2022, 24, i168-i169.	1.2	0
16	OTHR-32. The Pediatric Targeted Therapy 2.0 registry: robust molecular diagnostics for precision oncology. <i>Neuro-Oncology</i> , 2022, 24, i154-i154.	1.2	0
17	PATH-13. Methylation analysis in the diagnosis of pediatric CNS tumors; a single center experience. <i>Neuro-Oncology</i> , 2022, 24, i161-i161.	1.2	0
18	LGG-17. Preventing recurrence: targeting molecular mechanisms driving tumor growth rebound after MAPKi withdrawal in pediatric low-grade glioma. <i>Neuro-Oncology</i> , 2022, 24, i91-i91.	1.2	0

#	ARTICLE	IF	CITATIONS
19	LGG-18. Inhibition of Bcl-xL targets the senescent compartment of pilocytic astrocytoma. <i>Neuro-Oncology</i> , 2022, 24, i91-i92.	1.2	0
20	LGG-27. Molecular implications of mitogen-activated protein kinase pathway inhibition by the MEK inhibitor trametinib in BRAF-fusion-driven pediatric pilocytic astrocytoma. <i>Neuro-Oncology</i> , 2022, 24, i94-i94.	1.2	0
21	LGG-26. Predicting MAPK inhibitor sensitivity in pediatric low-grade gliomas with novel gene expression-derived signatures. <i>Neuro-Oncology</i> , 2022, 24, i93-i94.	1.2	0